Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
University of South Florida
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06103734CT.gov A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants | — | Withdrawn | — | — | — |
NCT06985342CT.gov Acute Migraine Treatment in the ED With Gepants | — | Terminated | — | — | — |
NCT06995729CT.gov A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | — | Recruiting | — | — | — |
NCT06401642CT.gov Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications | — | Recruiting | — | — | — |
NCT05989048CT.gov A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults | — | Completed | — | — | — |
NCT04804033CT.gov A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention | — | Terminated | — | — | — |
NCT04571060CT.gov Randomized Trial in Adult Participants With Acute Migraines | — | Completed | — | — | — |
NCT04408794CT.gov Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine | — | Completed | — | — | — |
NCT03872453CT.gov Acute Treatment Trial in Adult Subjects With Migraines | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Zavegepant (this asset) | University of South Florida | Approved | BB · 70 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Eptinezumab | Stanford University | P4 | BBB |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Galcanezumab | Stanford University | P4 | BBB |
+42 more in the Migraine Disorder cohort
Other indications for Zavegepant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Without Aura | — | P1 | CC · 43 |
| Migraine With Aura | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Zavegepant in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/zavegepant-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →